Fichtenbaum, C. J., Malvestutto, C. D., Watanabe, M. G., Smith, E. D., Ribaudo, H. J., McCallum, S., … Grinspoon, S. K. (2024). Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 27, pp. 89–90).

Fichtenbaum, C. J., C. D. Malvestutto, M. G. Watanabe, E. D. Smith, H. J. Ribaudo, S. McCallum, K. V. Fitch, et al. “Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 27:89–90, 2024.

Fichtenbaum CJ, Malvestutto CD, Watanabe MG, Smith ED, Ribaudo HJ, McCallum S, et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2024. p. 89–90.

Fichtenbaum, C. J., et al. “Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial.” JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 27, 2024, pp. 89–90.

Fichtenbaum CJ, Malvestutto CD, Watanabe MG, Smith ED, Ribaudo HJ, McCallum S, Fitch KV, Currier JS, Diggs M, Aberg JA, Lu MT, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Bloomfield GS, Douglas PS, Zanni MV, Grinspoon SK. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2024. p. 89–90.